Skip to main content

Table 2 Additional contribution of positive 14-3-3η to identify rheumatoid arthritis amongst patients with early inflammatory arthritis

From: Serum levels of 14-3-3η protein supplement C-reactive protein and rheumatoid arthritis-associated antibodies to predict clinical and radiographic outcomes in a prospective cohort of patients with recent-onset inflammatory polyarthritis

  1987+/2010+ 1987+/2010– 1987–/2010+ 1987–/20– Total Incremental benefit of 14-3-3η
  (n = 252) number (%) (n = 23) number (%) (n = 29) number (%) (n = 26) number (%) (n = 330a) number (%)
Rheumatoid factor+ 140 (55.6) 0 (0) 6 (20.7) 0 (0) 146 (44.2) NA
Anti-CCP2+ 119 (47.2) 0 (0) 14 (48.3) 0 (0) 133 (40.3) NA
Anti-Sa+ 67 (26.6) 0 (0) 6 (20.7) 0 (0) 73 (22.1) NA
Rheumatoid factor + and/or anti-CCP2+ 153 (60.7) 0 (0) 14 (48.3) 0 (0) 167 (50.6) NA
Rheumatoid factor + and/or anti-CCP2+ and/or anti-Sa+ 155 (61.5) 0 (0) 15 (51.7) 0 (0) 170 (51.5) NA
14-3-3η ≥0.19 ng/ml 134 (50.6) 1 (10) 14 (43.8) 4 (17.4) 153 (46.4) NA
14-3-3η ≥0.50 ng/ml 111 (44.0) 0 (0) 8 (27.6) 0 (0) 119 (36.1) NA
14-3-3η ≥ 0.19 ng/ml and/or       
Rheumatoid factor+ 161 (63.9) 1 (4.3) 15 (51.7) 4 (15.4) 181 (54.8) 24.0 %***
Anti-CCP2+ 158 (62.7) 1 (4.3) 19 (65.5) 4 (15.4) 182 (55.2) 36.8 %***
Anti-Sa+ 144 (57.1) 1 (4.3) 15 (51.7) 4 (15.4) 164 (49.7) 124.7 %***
Rheumatoid factor + and/or anti-CCP2+ 168 (66.7) 1 (4.3) 19 (65.5) 4 (15.4) 192 (58.2) 15.0 %***
Rheumatoid factor + and/or anti-CCP2+ and/or anti-Sa+ 170 (64.2) 1 (10) 19 (59.4) 4 (17.4) 194 (58.8) 14.1 %***
14-3-3η ≥ 0.50 ng/ml and/or       
Rheumatoid factor+ 150 (59.5) 0 (0) 9 (31.0) 0 (0) 159 (48.2) 8.9 %***
Anti-CCP2+ 147 (58.3) 0 (0) 15 (51.7) 0 (0) 162 (49.1) 21.8 %***
Anti-Sa+ 126 (50.0) 0 (0) 11 (37.9) 0 (0) 137 (41.5) 87.7 %***
Rheumatoid factor + and/or anti-CCP2+ 159 (63.1) 0 (0) 15 (51.7) 0 (0) 174 (52.7) 4.2 %**
Rheumatoid factor + and/or anti-CCP2+ and/or anti-Sa+ 161 (63.9) 0 (0) 16 (55.2) 0 (0) 177 (53.6) 4.1 %**
  1. aData insufficient to assess 2010 American College of Rheumatology/European League Against Rheumatism criteria in one patient; **p <0.01; ***p <0.001. Anti CCP2 antibodies to citrullinated peptides, second generation. NANot applicable